JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170

Benzinga Newsdesk www.benzinga.com Positive 74.9%

Neg 0% Neu 0% Pos 74.9%

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $160 to $170.